Akebia Therapeutics
AKBA
143 hedge funds and large institutions have $294M invested in Akebia Therapeutics in 2020 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 46 increasing their positions, 52 reducing their positions, and 38 closing their positions.
173% more call options, than puts
Call options by funds: $6.42M | Put options by funds: $2.35M
10% more capital invested
Capital invested by funds: $268M → $294M (+$26.2M)
0.75% more ownership
Funds ownership: 71.06% → 71.81% (+0.75%)
12% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 52
13% less funds holding
Funds holding: 164 → 143 (-21)
55% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$20.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.6M |
| 3 |
Goldman Sachs
New York
|
+$6.28M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.46M |
| 5 |
Renaissance Technologies
New York
|
+$4.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$18.4M |
| 2 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
-$14.2M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$8.98M |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$4.99M |
| 5 |
D.E. Shaw & Co
New York
|
-$4.71M |
AKBA Hedge Fund Activity: Q4 2020 in Review
143 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q4 2020, worth a combined $294M — up 9.8% from $268M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of AKBA and 17 opened new positions — a net loss of 21 holders — while 52 trimmed existing stakes and 46 added.
The largest buyer was State Street, adding an estimated $20.8M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $18.4M sold.
- 143 institutional investors held Akebia Therapeutics (AKBA) as of Q4 2020, down from 164 in Q3 2020.
- Funds reported $294M of Akebia Therapeutics stock for Q4 2020, up 9.8% quarter-over-quarter.
- 17 funds opened new Akebia Therapeutics positions in Q4 2020 and 38 closed out, a net change of -21 holders.
- The largest Akebia Therapeutics buyer in Q4 2020 was State Street, an estimated $20.8M added.
- The largest Akebia Therapeutics seller in Q4 2020 was Avidity Partners Management, an estimated $18.4M sold.
Based on aggregated 13F filings for Q4 2020.